Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Huons Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner and a distinct art unit. The company's current prosecution activity is limited to this single pending action, which represents the whole of its active engagement with the USPTO. In the biotechnology sector, this 1 pending office action is the sole focus of the company's current efforts to secure intellectual property rights, making its resolution a critical milestone for the portfolio.
STOCKTON, LAURA LYNNE is the busiest examiner for this portfolio, holding 1 pending office action. This examiner is responsible for the company's only active matter. The concentration in a distinct art unit indicates that the pending biotechnology matter is being reviewed within a single specialized examination group. Because the company is working with a single distinct examiner on its 1 pending office action, its current patent strategy is focused on meeting the specific technical and legal requirements set forth by this individual within the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246773 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | STOCKTON, LAURA LYNNE | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246773 | MLKL BINDING OR DEGRADING COMPOUND AND PHARMACEUTICAL USE THEREOF | STOCKTON, LAURA LYNNE | 1626 | §112 | Final Rejection | — | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHuons Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Laura Lynne Stockton has the most, with 1 of Huons Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.